Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr;70(4):e30060.
doi: 10.1002/pbc.30060. Epub 2022 Nov 1.

Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma

Affiliations
Editorial

Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma

Markus G Seidel et al. Pediatr Blood Cancer. 2023 Apr.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45(3):256-264.
    1. Büttgen K, Levy M. Juvenile xanthogranuloma (JXG). In: Corona R, ed. UpToDate ®. Wolters Kluwer; 2021.
    1. Rajendra B, Duncan A, Parslew R, Pizer BL. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer. 2009;52(3):413-415.
    1. Maintz L, Wenzel J, Irnich M, Reinhard H, Bieber T. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol. 2017;176(2):481-487.
    1. Histiocyte_Society, Histiocytosis NACf, Minkov M. NCT02205762: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis. Vol. 2022. U.S. National Library of Medicine: National Institutes of Health; 2014.

Publication types

MeSH terms

Substances